PET/CT with [18F]FDG in Ovarian Cancer
The role of [18F]FDG-PET/CT for differentiating between malignant and benign ovarian tumors remains controversial, and false-negative and false-positive cases have been reported. Concerning the prognostic value of [18F]FDG-PET/CT, there have been reports that a high (>13.15) pretreatment SUVmax of the primary tumor in patients with ovarian cancer was associated with a poor prognosis . The SUVmax of the primary tumor had a statistically significant association with stage (p = 0.010) and histology (p = 0.001) .
- 2.Yuan Y, Gu ZX, Tao XF, Liu SY (2012) Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis. Eur J Radiol 81:1002–1006CrossRefGoogle Scholar
- 3.Castelluci P, Perrone AM, Picchio M, Ghi T, Farsad M, Nanni C et al (2007) Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun 28:589–595CrossRefGoogle Scholar
- 31.Evangelista L, Palma MD, Gregianin M et al (2015) Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients. J Turk Ger Gynecol Assoc 16:137–144CrossRefGoogle Scholar
- 32.Sanli Y, Turkmen C, Bakir B, Iyibozkurt C, Ozel S, Has D, Yilmaz E, Topuz S, Yavuz E, Unal SN, Mudun A (2012) Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer. Nucl Med Commun 33:509–515CrossRefGoogle Scholar